leadf
logo-loader
viewAmryt Pharma PLC

Amryt Pharma presents at the Proactive One2One virtual conference

Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference.

Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases.

The company recently outligned plans to share additional encouraging data on its recent successful phase III study of FILSUVEZ to the medical and financial communities.

 

Quick facts: Amryt Pharma PLC

Price: 195 GBX

AIM:AMYT
Market: AIM
Market Cap: £317.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results. The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide. Wiley talks...

4 weeks ago

2 min read